Regeneron Pharmaceuticals, Inc.
) highly successful eye drug is in the news again with the U.S.
Food and Drug Administration (FDA) accepting the company's
marketing application for another indication, macular edema
following branch retinal vein occlusion (BRVO). Shares showed a
positive movement following the FDA's move.
Regeneron had submitted the marketing application for BRVO -
the fourth indication to be filed in the U.S. for Eylea - on the
basis of encouraging data from a phase III study (VIBRANT). The
regulatory application for Eylea for the additional indication
has been accepted for standard review by the U.S. regulatory body
with a decision expected by Oct 23, 2014 (action date).
This is the second FDA action date on Eylea this year as
Regeneron seeks to expand the drug's label beyond the approved
eye disorders -- neovascular (wet) age-related macular
degeneration (AMD) and macular edema following central retinal
vein occlusion (CRVO). The FDA is expected to decide on
Regeneron's application seeking to market Eylea for the diabetic
macular edema (DME) indication by Aug 18, 2014.
Sales of the drug have been on the rise ever since its U.S.
launch in late 2011 for the wet AMD indication. In Sep 2012, the
FDA approved the label expansion of Eylea into the macular edema
following CRVO indication.
Sales of Eylea in the U.S. climbed 46% in the fourth quarter
of 2013 to $402 million. Regeneron expects Eylea to record 2014
U.S. sales in the range of $1.7-$1.8 billion, well above the $1.4
billion recorded in 2013. The guidance assumes that Eylea will be
cleared in the U.S. for DME in the third quarter of this
We note that Eylea's success is not limited to the U.S. The
drug, which has been cleared in many ex-U.S. markets for the wet
AMD and CRVO indications, came up with fourth quarter 2013 sales
of $184 million (up 47% sequentially) in these markets as
reported by partner
). We believe investor focus will remain on updates regarding
Regeneron, a biopharmaceutical company, carries a Zacks Rank
#3 (Hold). Better-ranked biopharma stocks include
Gilead Sciences, Inc.
). Both stocks carry a Zacks Rank #1 (Strong Buy).
ALEXION PHARMA (ALXN): Free Stock Analysis
BAYER A G -ADR (BAYRY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
REGENERON PHARM (REGN): Free Stock Analysis
To read this article on Zacks.com click here.